Author

Eshwar Meduri

Wellcome/MRC Cambridge Stem Cell InstituteORCID 0000-0002-3821-312XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Research Focus:perturbation response prediction· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Albert KoulmaniD· 1 shared Alicia Garcia-GimeneziD· 1 shared Benjamin JenkinsiD· 1 shared Brian J.P. HuntlyiD· 1 shared Cécile K. LopeziD· 1 shared David O’ConnoriD· 1 shared Dhoyazan AzaziiD· 1 shared George GiotopoulosiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Albert KoulmanORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyNature CommunicationsPeer-reviewedMay 20, 2025

Genetic or pharmacological inactivation of CREBBP sensitizes B-cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition

Alicia Garcia-Gimenez, Jonathan E. Ditcham, Dhoyazan Azazi…·Simon E. Richardson

This study identifies CREBBP mutations as a targetable vulnerability in B-ALL, showing that CREBBP inhibition sensitizes these cells to Venetoclax-induced ferroptosis.

19 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky